ArticlePloS one2026
The KEAP1/NRF2 axis controls LPS-induced oxidative stress, inflammasome activation and caspase-1 activity in human endothelial cells.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Endothelial cells play a critical role in the inflammatory response during sepsis, however, their metabolic adaptations to inflammatory stimuli remain much less characterized compared to immune cells. Here, we demonstrate that Human Umbilical Vein Endothelial Cells (HUVECs) do not undergo the metabolic and respiratory rewiring typically observed in macrophages following lipopolysaccharide (LPS) stimulation, a common model of inflammation during sepsis. A key metabolite in LPS-activated macrophages is itaconate, which is known for its anti-inflammatory properties. Although HUVECs do not naturally produce itaconate, we explored whether exogenous administration of the cell-permeable derivative 4-octyl itaconate (4-OI) could modulate their response to LPS. Remarkably, 4-OI treatment significantly reduced mitochondrial reactive oxygen species (mitoROS) levels in LPS-treated HUVECs, restoring them to baseline levels. This antioxidant effect was accompanied by a pronounced decrease in inflammasome activation, including suppression of ASC speck formation and caspase-1 activation. These findings suggest that 4-OI could protect endothelial cells from inflammation during sepsis in a manner similar to its role in macrophages. Mechanistically, 4-OI acts through the KEAP1/NRF2 antioxidant pathway. Silencing of KEAP1, the direct molecular target of 4-OI, resulted in a pronounced upregulation of NRF2 target genes, particularly HMOX1, with modest effects on NQO1 and no change in GCLC. NRF2 knockdown decreased HMOX1 expression and blunted 4-OI's effects, although some residual induction persisted. Further confirming the importance of this pathway, KEAP1 silencing itself suppressed LPS-induced mitoROS, ASC speck formation, and caspase-1 activation, mimicking 4-OI treatment. Taken together, these results demonstrate that 4-OI protects endothelial cells from LPS-induced oxidative stress and inflammation primarily via the KEAP1/NRF2 axis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.